Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2019-10-16 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Ytterligare europeiskt patentbeviljande för Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces that the European Patent Office (EPO) has granted an additional European patent to Episurf Medical for its 3D-based damage marking technology. It includes quotes from the COO and general company information. The final paragraph states that the information is required to be made public under the EU Market Abuse Regulation (MAR) and was released at a specific time on October 16, 2019. This type of announcement, concerning intellectual property rights and regulatory disclosure under MAR, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, SHA, CAP). It is a general regulatory announcement concerning a material event (patent grant) that must be disclosed publicly. Therefore, the most appropriate classification is the general regulatory filing fallback category.
2019-10-16 Swedish
UK patent approval for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a specific event: the UK Intellectual Property Office issuing an 'Intention to Grant for a patent' related to the company's technology. This is a specific regulatory or legal development concerning intellectual property. It is not a standard financial report (10-K, IR, ER), a management change (MANG), or a director's trade (DIRS). While it relates to legal/IP matters, it is a specific announcement rather than a general legal proceeding report (LTR). Given the options, this type of specific, non-financial, non-governance regulatory update that doesn't fit other categories is best classified as a general Regulatory Filing (RNS), as it is an obligatory disclosure under EU Market Abuse Regulation, but concerns IP, not standard financial performance or corporate governance.
2019-10-14 English
Brittiskt patentbeviljande för Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces that the UK Patent Office intends to grant a patent for Episurf Medical's 3D-based damage marking technology, which is part of the Episealer® implant system. This is a specific announcement regarding intellectual property (patent grant). Among the provided categories, there is no direct code for a 'Patent Grant Announcement'. However, the content is a specific regulatory/legal update concerning the company's assets and protection. It is not an earnings release (ER), interim report (IR), management discussion (MDA), or a general regulatory filing (RNS) which is usually a fallback for miscellaneous items. Since it relates to legal protection and official regulatory action (patent office decision), it is closest to a Legal Proceedings Report (LTR) in scope, as patents are a form of legal protection, or potentially RNS if LTR is strictly for litigation. Given the context of official regulatory action regarding IP, and lacking a specific 'Patent' code, RNS (Regulatory Filings) is the most appropriate general category for this type of specific, non-financial, non-governance announcement that is mandated for public disclosure (as indicated by the final paragraph referencing EU Market Abuse Regulation). The document length is short (1779 chars), but it is the primary content, not an announcement *of* another report.
2019-10-14 Swedish
Ytterligare patentbeviljande i USA för Episurf Medical
Regulatory Filings Classification · 1% confidence The document is a short press release written in Swedish announcing that the USPTO intends to grant an additional patent for Episurf Medical concerning their Episealer® technology. It includes commentary from the COO, contact information, a boilerplate 'About Us' section, and concludes with a statement that the information is required to be made public under EU Market Abuse Regulation (MAR) and was released on October 8, 2019. This type of announcement, which details a specific legal/intellectual property event (patent grant intention) and is not a standard financial report (10-K, IR, ER), nor a director's dealing (DIRS), nor a general capital change (CAP/SHA), fits best under the general category for regulatory announcements or specific legal updates. Since it is a specific update regarding intellectual property protection and legal matters, it is most closely related to 'Legal Proceedings Report' (LTR) if it were a lawsuit, but since it is a positive IP development announcement, and it is not a standard financial filing, the most appropriate general category for non-standard regulatory news is 'Regulatory Filings' (RNS), as it is a mandatory disclosure under MAR that doesn't fit the other specific codes. Given the content is purely about IP protection, 'LTR' might be considered, but 'RNS' is the safer fallback for mandatory, non-financial, non-management change regulatory news.
2019-10-08 Swedish
Another US patent approval for Episurf Medical
Legal Proceedings Report Classification · 1% confidence The document announces the receipt of a Notice of Allowance from the USPTO for a US patent related to the company's Episealer® Femoral Twin joint implant. This is a specific update regarding intellectual property (IP) protection. While 'IP' is not an explicit category, the content strongly relates to the company's assets and legal/regulatory standing concerning its technology. Given the options, 'Legal Proceedings Report (LTR)' is the closest fit as patent approvals/disputes fall under legal/regulatory matters concerning assets, although 'Regulatory Filings (RNS)' is a strong fallback. However, since this is a specific announcement about a patent grant, which is a form of regulatory/legal milestone, LTR is chosen over the general RNS, as it pertains to a specific legal asset protection event. The document is short and is an announcement, not a comprehensive report.
2019-10-08 English
Dr. Kevin D. Plancher appointed Lead Investigator for Episurf’s Episealer® IDE study
Regulatory Filings Classification · 1% confidence The document announces the appointment of Dr. Kevin D. Plancher as the Lead Investigator for Episurf's Episealer® IDE clinical study. This is a specific announcement regarding personnel changes related to medical/clinical operations, which falls under the category of changes in senior personnel or key operational roles. This aligns best with the 'Board/Management Information' (MANG) definition, as a Lead Investigator in a major clinical trial acts as a key medical advisor and operational leader for that study, similar to a senior management role for the trial itself. It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), but a specific personnel announcement.
2019-10-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.